|
|
|
|
| LEADER |
03923nam a2200457 4500 |
| 001 |
on1018225386 |
| 003 |
OCoLC |
| 005 |
20180501122038.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
171018s2017 xx o 001 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|c YDX
|d N$T
|d EBLCP
|d IDEBK
|d OPELS
|d OCLCF
|d UPM
|d GZM
|d D6H
|d GrThAP
|
| 019 |
|
|
|a 1006380904
|a 1006602460
|
| 020 |
|
|
|a 9780444639493
|q (electronic bk.)
|
| 020 |
|
|
|a 0444639497
|q (electronic bk.)
|
| 020 |
|
|
|a 0444639489
|
| 020 |
|
|
|a 9780444639486
|
| 035 |
|
|
|a (OCoLC)1018225386
|z (OCoLC)1006380904
|z (OCoLC)1006602460
|
| 050 |
|
4 |
|a RM302.5
|
| 072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 615.7/042
|2 23
|
| 049 |
|
|
|a TEFA
|
| 245 |
0 |
0 |
|a Side effects of drugs annual.
|n 39 :
|b a worldwide yearly survey of new data in adverse drug reactions /
|c Sidhartha D. Ray, editor.
|
| 264 |
|
1 |
|a [Place of publication not identified] :
|b Elsevier,
|c 2017.
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 505 |
0 |
|
|a ""Front Cover""; ""A Worldwide Yearly Survey of New Data in Adverse Drug Reactions""; ""Copyright""; ""Contributors""; ""Contents""; ""Preface""; ""Special Reviews in SEDA 39""; ""Table of Essays, Annuals 1â#x80;#x93;38""; ""Abbreviations""; ""ADRs, ADEs and SEDs: A Bird's Eye View""; ""Introduction""; ""Analysis of ADEs, ADRs, Side Effects and Toxicity""; ""Terminology""; ""EIDOS""; ""DoTS""; ""WHO Classification""; ""References on Adverse Drug Reactions""; ""Pharmacogenomics Considerations""; ""Enzymes and Transporters""; ""Human Leukocyte Antigens (HLA)""; ""Genetic Testing Technology""
|
| 505 |
8 |
|
|a ""Conclusion""""References""; ""Immunological Reactions""; ""Type I Reactions (IgE-Mediated Anaphylaxis; Immediate Hypersensitivity)""; ""Type II Reactions (Cytotoxic Reactions)""; ""Type III Reactions (Immune Complex Reactions)""; ""Type IV Reactions (Cell-Mediated or Delayed Hypersensitivity Reactions)""; ""Other Types of Reactions""; ""References""; ""Analysis of Toxicological Reactions""; ""Potentiation Reactions""; ""Examples:""; ""Synergistic Effect""; ""Additive Effect""; ""Examples:""; ""Antagonistic Effects""; ""Examples:""; ""References""; ""Grades of Adverse Drug Reactions""
|
| 505 |
8 |
|
|a SEDA-38, 1]""""Organs and Systems""; ""Cardiovascular""; ""Reproductive Systems""; ""Skin""; ""Drugâ#x80;#x93;Drug Interaction""; ""Methylxanthines""; ""Caffeine [SEDA-32, 14; SEDA-33, 11; SEDA-34, 6; SEDA-36, 1; SEDA-37, 1; SEDA-38, 1]""; ""Organs and Systems""; ""Cardiovascular""; ""Selective Norepinephrine Reuptake Inhibitors Atomoxetine [SEDA-34, 4; SEDA-36, 1; SEDA-37, 1; SEDA-38, 1]""; ""Organ and Systems""; ""Drug-Drug Interactions""; ""Vigilance Promoting Drugs""; ""Modafinil and Armodafinil [SEDA-34, 6; SEDA-36, 1; SEDA-37, 1; SEDA-38, 1]""; ""Organs and Systems""
|
| 505 |
8 |
|
|a ""Psychiatric""""Drugs That Suppress Appetite [SEDA-34, 8; SEDA-36, 1; SEDA-37, 1; SEDA-38, 1]""; ""Phentermine [SEDA-34, 8; SEDA-36, 1, SEDA-37, 1; SEDA-38, 1]""; ""Organs and Systems""; ""Gastrointestinal""; ""Parasympathomimetics [SEDA-34, 9, SEDA-36, 1; SEDA-37, 1; SEDA-38, 1]""; ""Donepezil [SEDA-34, 10; SEDA-36, 1; SEDA-37, 1; SEDA-38, 1]""; ""Organ and Systems""; ""Psychiatric""; ""Memantine [SEDA-34, 1]""; ""Organ and Systems""; ""Cardiovascular""; ""Rivastigmine [SEDA-34, 10; SEDA-36, 1; SEDA-37, 1; SEDA-38, 1]""; ""Organ and Systems""; ""Skin""; ""References""
|
| 500 |
|
|
|a Includes indexes.
|
| 588 |
0 |
|
|a Print version record.
|
| 650 |
|
0 |
|a Drugs
|x Side effects.
|
| 650 |
|
7 |
|a MEDICAL / Pharmacology.
|2 bisacsh
|
| 650 |
|
7 |
|a Drugs
|x Side effects.
|2 fast
|0 (OCoLC)fst00898912
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Ray, Sidhartha D.
|
| 776 |
0 |
8 |
|c Original
|z 0444639489
|z 9780444639486
|w (OCoLC)987359055
|
| 856 |
4 |
0 |
|u https://www.sciencedirect.com/science/bookseries/03786080/39
|z Full Text via HEAL-Link
|
